The global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025.
The growth of the pancreatic cancer therapy market is primarily attributed to the increase in number of therapies launched in the market. The development of new drugs is thus expected to drive the growth of pancreatic cancer therapy market. For instance, in October 2015, the FDA approved Onivyde drug by Merrimack Pharmaceuticals, Inc. as a part of treatment regimen for advanced pancreatic cancer. Some common side effects associated with chemotherapy drugs include diarrhea and abdominal cramping, fatigue, loss of appetite, change in food taste and others. Cancer cells that are rapidly growing are killed by chemotherapy drugs. However, these drugs travel throughout the body and thus can affect normal and healthy cells adversely. Blood-forming cells in the bone marrow, hair follicles and cell in the mouth, digestive tract, and reproductive system are likely to be affected by chemotherapeutic drugs. The current treatment options available for pancreatic cancer patients only help to extend the patients' lives by a few months. This demands potential drugs that are able to enhance the effectiveness of chemotherapy drugs. Combination of two or more chemotherapy drugs are a suitable way out to increase the efficacy of the drug as well as proves advantageous in the treatment.
Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the pancreatic cancer therapy market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this cancer is majorly occurring cancer type among the two and thus is expected to have massive patient pool over the forecast years.
Global pancreatic cancer therapy market, based on the therapy was segmented into biologic, chemotherapy and others. In 2017, biologic therapy segment held the largest share of the pancreatic cancer therapy market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.
Some of the major primary and secondary sources for pancreatic cancer therapy included in the report are World Health Organization (WHO), American Society of Clinical Oncology, Pancreatic Cancer Action Network, National Institutes of Health, National Cancer Institute, Scientific American, American Cancer Society and Pancreatic Cancer Research.
TABLE OF CONTENTS
1. INTRODUCTION 18
1.1 SCOPE OF THE STUDY 18
1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE 18
2. GLOBAL PANCREATIC CANCER THERAPY MARKET - KEY TAKEAWAYS 19
3. GLOBAL PANCREATIC CANCER THERAPY MARKET - MARKET LANDSCAPE 21
3.1 OVERVIEW 21
3.2 MARKET SEGMENTATION 21
3.3 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY TYPE 22
3.4 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY THERAPY 22
3.5 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY GEOGRAPHY 23
3.6 PEST ANALYSIS 24
 3.6.1 North America - PEST Analysis 24
 3.6.2 Europe- PEST Analysis 26
 3.6.3 Asia Pacific- PEST Analysis 28
 3.6.4 Middle East And Africa- PEST Analysis 30
 3.6.5 South and Central America - PEST Analysis 32
 
4. GLOBAL PANCREATIC CANCER THERAPY MARKET - KEY MARKET DYNAMICS 34
4.1 KEY MARKET DRIVERS 34
 4.1.1 Rise in Number of Patients Suffering with Pancreatic Cancer 34
 4.1.2 Increasing Healthcare Expenditures for Pancreatic Drugs 34
 4.1.3 Increase in Number of Therapies Launched in the Market 35
4.2 KEY MARKET RESTRAINTS 35
 4.2.1 Side Effects of the Therapies 35
 4.2.2 Low Success Rate of Treatments 35
4.3 KEY MARKET OPPORTUNITIES 36
 4.3.1 Development of Efficient Therapy for Pancreatic Cancer Treatment 36
4.4 FUTURE TRENDS 36
 4.4.1 Rapid Adoption of Combination Therapy Over Monotherapy 36
4.5 IMPACT ANALYSIS 37
5. PANCREATIC CANCER THERAPY MARKET - GLOBAL ANALYSIS 38
5.1 GLOBAL PANCREATIC CANCER THERAPY MARKET REVENUE FORECASTS AND ANALYSIS 38
5.2 GLOBAL PANCREATIC CANCER THERAPY MARKET, BY GEOGRAPHY - FORECASTS AND ANALYSIS 39
5.3 EXPERT OPINIONS 40
6. PANCREATIC CANCER THERAPY MARKET ANALYSIS- BY TYPE 41
6.1 OVERVIEW 41
 6.1.1 Endocrine Pancreatic Cancer 42
 6.1.2 Overview 42
 6.1.3 Global Endocrine Pancreatic Cancer Therapy Market Revenue and Forecasts to 2025 (US$ Mn) 42
 6.1.4 Exocrine Pancreatic Cancer 43
 6.1.4.1 Overview 43
 6.1.4.2 Global Exocrine Pancreatic Cancer Therapy market Revenue and Forecasts to 2025 (US$ Mn) 43
 
7. GLOBAL PANCREATIC CANCER THERAPY MARKET ANALYSIS- BY THERAPY 44
7.1 OVERVIEW 44
7.2 BIOLOGIC THERAPY 45
 7.2.1 Overview 45
 7.2.2 Global Biologic Therapy Market Revenue and Forecasts to 2025 (US$ Mn) 45
7.3 CHEMOTHERAPY 46
 7.3.1 Overview 46
 7.3.2 Global Chemotherapy Market Revenue and Forecasts to 2025 (US$ Mn) 46
 7.4 OTHERS 47
 7.4.1 Overview 47
 7.4.2 Global Others Market Revenue and Forecasts to 2025 (US$ Mn) 47
 
8. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 48
8.1 OVERVIEW 48
8.2 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 49
8.3 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 49
8.4 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 50
8.5 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 50
8.6 US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 51
8.7 US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 52
 8.7.1 US Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 52
 8.7.2 US Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 53
8.8 CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
8.9 CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
 8.9.1 Canada Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 55
 8.9.2 Canada Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 55
8.10 MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
8.11 MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
 8.11.1 Mexico Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 57
 8.11.2 Mexico Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 57
 
9. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 58
9.1 OVERVIEW 58
9.2 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 59
9.3 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 59
9.4 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 60
9.5 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 60
9.6 GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 61
 9.6.1 Germany Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 62
 9.6.2 Germany Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 62
 9.6.3 Germany Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 63
9.7 UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 63
 9.7.1 UK Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 64
 9.7.2 UK Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 64
 9.7.3 UK Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 65
9.8 FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 66
 9.8.1 France Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 66
 9.8.2 France Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 67
 9.8.3 France Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 67
 
10. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 68
10.1 OVERVIEW 68
10.2 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 69
10.3 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 69
10.4 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 70
10.5 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 70
10.6 JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
10.7 JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
 10.7.1 Japan Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 72
 10.7.2 Japan Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 72
10.8 CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
10.9 CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
 10.9.1 China Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 74
 10.9.2 China Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 74
10.10 INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 75
10.11 INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 76
 10.11.1 India Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 76
 10.11.2 India Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 77
 
11. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 78
11.1 OVERVIEW 78
11.2 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 79
11.3 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 79
11.4 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 80
11.5 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 80
11.6 UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
11.7 UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
 11.7.1 UAE Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 82
 11.7.2 UAE Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 82
11.8 SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 82
11.9 SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 83
 11.9.1 Saudi Arabia Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 83
 11.9.2 Saudi Arabia Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 84
11.10 SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 84
11.11 SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 85
 11.11.1 South Africa Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 85
 11.11.2 South Africa Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 86
 
12. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 87
12.1 OVERVIEW 87
12.2 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 88
12.3 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 88
12.4 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 89
12.5 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET SHARE, BY COUNTRY (2017 & 2025) (%) 89
12.6 BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 90
 12.6.1 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025 (US$ Mn) 90
 12.6.2 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 91
 12.6.3 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 91
 
13. PANCREATIC CANCER THERAPY MARKET -INDUSTRY LANDSCAPE 92
13.1 OVERVIEW 92
13.2 GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 92
13.3 ORGANIC DEVELOPMENTS 92
 13.3.1 Overview 92
13.4 ORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 93
13.5 CLINICAL TRIALS 93
 13.5.1 Recent Clinical Trials By Players In The Pancreatic Cancer Therapy Market 93
13.6 PRODUCT APPROVAL 94
 13.6.1 Recent Product Approval By Players In The Pancreatic Cancer Therapy Market 94
13.7 OTHERS 94
 13.7.1 Other Organic Developments In The Pancreatic Cancer Therapy Market 94
13.8 INORGANIC DEVELOPMENTS 95
 13.8.1 Overview 95
13.9 INORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 95
13.10 COLLABORATION 96
 13.10.1 Recent Collaborations by Players in the Pancreatic Cancer Therapy Market 96
13.11 OTHERS 96
 13.11.1 Other Organic Developments In The Pancreatic Cancer Therapy Market 96
 
14. PANCREATIC CANCER THERAPY MARKET -KEY COMPANY PROFILES 97
14.1 ELI LILLY AND COMPANY 97
 14.1.1 Key Facts 97
 14.1.2 Business Description 97
 14.1.3 Financial Overview 98
 14.1.4 Product Portfolio 98
 14.1.5 SWOT Analysis 98
 14.1.6 Key Developments 99
14.2 F. HOFFMANN-LA ROCHE LTD. 100
 14.2.1 Key Facts 100
 14.2.2 Business Description 100
 14.2.3 Financial Overview 101
 14.2.4 Product Portfolio 101
 14.2.5 Product Pipeline 101
 14.2.6 SWOT Analysis 102
 14.2.7 Key Developments 102
14.3 AMGEN INC. 103
 14.3.1 Key Facts 103
 14.3.2 Business Description 103
 14.3.3 Financial Overview 104
 14.3.4 Product Portfolio 104
 14.3.5 Product Pipeline 104
 14.3.6 SWOT Analysis 105
 14.3.7 Key Developments 105
14.4 NOVARTIS AG 106
 14.4.1 Key Facts 106
 14.4.2 Business Description 106
 14.4.3 Financial Overview 107
 14.4.4 Product Portfolio 107
 14.4.5 Product Pipeline 107
 14.4.6 SWOT Analysis 108
 14.4.7 Key Developments 108
14.5 CELGENE CORPORATION 109
 14.5.1 Key Facts 109
 14.5.2 Business Description 109
 14.5.3 Financial Overview 110
 14.5.4 Product Portfolio 110
 14.5.5 SWOT Analysis 110
 14.5.6 Key Developments 111
14.6 MERCK & CO., INC. 112
 14.6.1 Key Facts 112
 14.6.2 Business Description 112
 14.6.3 Financial Overview 113
 14.6.4 Product Portfolio 113
 14.6.5 Product Pipeline 113
 14.6.6 SWOT Analysis 114
 14.6.7 Key Developments 114
14.7 PHARMACYTE BIOTECH INC. 116
 14.7.1 Key Facts 116
 14.7.2 Business Description 116
 14.7.3 Financial Overview 117
 14.7.4 Product Portfolio 117
 14.7.5 SWOT Analysis 117
 14.7.6 Key Developments 118
14.8 CLOVIS ONCOLOGY 119
 14.8.1 Key Facts 119
 14.8.2 Business Description 119
 14.8.3 Financial Overview 120
 14.8.4 Product Portfolio 120
 14.8.5 SWOT Analysis 120
 14.8.6 Key Developments 120
14.9 TEVA PHARMACEUTICAL INDUSTRIES LTD 121
 14.9.1 Key Facts 121
 14.9.2 Business Description 121
 14.9.3 Financial Overview 122
 14.9.4 Product Portfolio 122
 14.9.5 SWOT Analysis 122
 14.9.6 Key Developments 122
14.10 PFIZER INC. 123
 14.10.1 Key Facts 123
 14.10.2 Business Description 123
 14.10.3 Financial Overview 124
 14.10.4 Product Portfolio 124
 14.10.5 SWOT Analysis 124
 14.10.6 Key Developments 125
 
15. APPENDIX 126
15.1 ABOUT THE PUBLISHER 126
15.2 GLOSSARY OF TERMS 127
15.3 METHODOLOGY 129
 15.3.1 Coverage 130
 15.3.2 Secondary Research 131
 15.3.3 Primary Research 131
 
 
 
LIST OF TABLES
TABLE 1. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 49
TABLE 2. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 50
TABLE 3. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 52
TABLE 4. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 53
TABLE 5. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 55
TABLE 6. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 55
TABLE 7. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 57
TABLE 8. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 57
TABLE 9. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 59
TABLE 10. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 60
TABLE 11. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 62
TABLE 12. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 63
TABLE 13. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 64
TABLE 14. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 65
TABLE 15. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 67
TABLE 16. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 67
TABLE 17. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 69
TABLE 18. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 70
TABLE 19. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 70
TABLE 20. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 72
TABLE 21. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 72
TABLE 22. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 74
TABLE 23. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 74
TABLE 24. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 76
TABLE 25. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 77
TABLE 26. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 79
TABLE 27. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 80
TABLE 28. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 82
TABLE 29. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 82
TABLE 30. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 83
TABLE 31. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 84
TABLE 32. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 85
TABLE 33. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 86
TABLE 34. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 88
TABLE 35. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 89
TABLE 36. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 91
TABLE 37. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$MN) 91
TABLE 38. RECENT CLINICAL TRIALS IN THE PANCREATIC CANCER THERAPY MARKET 93
TABLE 39. RECENT PRODUCT APPROVAL IN THE PANCREATIC CANCER THERAPY MARKET 94
TABLE 40. OTHER ORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET 94
TABLE 41. RECENT COLLABORATIONS IN THE PANCREATIC CANCER THERAPY MARKET 96
TABLE 42. OTHER ORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET 96
TABLE 43. GLOSSARY OF TERMS, PANCREATIC CANCER THERAPY MARKET 127
LIST OF FIGURES
FIGURE 1. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET, REVENUE (US$ MN), BY GEOGRAPHY 2018 & 2025 19
FIGURE 2. GLOBAL PANCREATIC CANCER THERAPY MARKET BY TYPE, MARKET SHARE (%), 2017 20
FIGURE 3. GLOBAL PANCREATIC CANCER THERAPY MARKET BY THERAPY, MARKET SHARE (%), 2017 20
FIGURE 4. GLOBAL PANCREATIC CANCER THERAPY MARKET SEGMENTATION 21
FIGURE 5. GLOBAL PANCREATIC CANCER THERAPY MARKET SEGMENTATION, BY REGION 22
FIGURE 6. NORTH AMERICA PEST ANALYSIS 24
FIGURE 7. EUROPE PEST ANALYSIS 26
FIGURE 8. ASIA PACIFIC PEST ANALYSIS 28
FIGURE 9. MIDDLE EAST AND AFRICA PEST ANALYSIS 30
FIGURE 10. SOUTH AND CENTRAL AMERICA PEST ANALYSIS 32
FIGURE 11. PANCREATIC CANCER THERAPY MARKET IMPACT ANALYSIS OF DRIVER AND RESTRAINTS 37
FIGURE 12. GLOBAL PANCREATIC CANCER THERAPY MARKET REVENUE FORECASTS AND ANALYSIS - 2017- 2025 38
FIGURE 13. GLOBAL PANCREATIC CANCER THERAPY MARKET - BY GEOGRAPHY FORECASTS AND ANALYSIS - 2017- 2025 39
FIGURE 14. GLOBAL PANCREATIC CANCER THERAPY MARKET BREAKDOWN, BY PRODUCT 2017 & 2025 (%) 41
FIGURE 15. GLOBAL ENDOCRINE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 42
FIGURE 16. GLOBAL EXOCRINE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 43
FIGURE 17. GLOBAL PANCREATIC CANCER THERAPY MARKET SHARE, BY THERAPY 2017 & 2025 (%) 44
FIGURE 18. GLOBAL BIOLOGIC THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 45
FIGURE 19. GLOBAL CHEMOTHERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 46
FIGURE 20. GLOBAL OTHERS MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 47
FIGURE 21. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 48
FIGURE 22. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 49
FIGURE 23. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 50
FIGURE 24. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 52
FIGURE 25. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
FIGURE 26. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
FIGURE 27. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 58
FIGURE 28. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 59
FIGURE 29. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 60
FIGURE 30. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 62
FIGURE 31. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 64
FIGURE 32. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 66
FIGURE 33. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 68
FIGURE 34. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 69
FIGURE 35. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
FIGURE 36. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
FIGURE 37. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 76
FIGURE 38. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 78
FIGURE 39. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 79
FIGURE 40. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 80
FIGURE 41. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
FIGURE 42. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 83
FIGURE 43. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 85
FIGURE 44. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 87
FIGURE 45. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 88
FIGURE 46. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET SHARE, BY COUNTRY (2017 & 2025) (%) 89
FIGURE 47. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 90
FIGURE 48. GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 92
FIGURE 49. ORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 93
FIGURE 50. INORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 95
The List of Companies
1. Eli Lilly and Company
2. F. Hoffmann-La Roche AG
3. Celgene Corporation
4. Amgen Inc.
5. Novartis AG
6. Pharmacyte Biotech Inc.
7. Clovis Oncology
8. Teva Pharmaceutical Industries Ltd.
9. Pfizer Inc.
10. Merck & Co., Inc.